{"id":983718,"date":"2026-07-22T16:23:24","date_gmt":"2026-07-22T20:23:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/"},"modified":"2026-07-22T16:23:24","modified_gmt":"2026-07-22T20:23:24","slug":"okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/","title":{"rendered":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LONDON and NEW YORK, July  22, 2026  (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EaIZsWh3V2VuFDaF-gHxinFDLXYYoky9-MQ5oG5zc1N_zzrhry6t9tv74IUCjqbb7EqYHkZhyOAfs8KjAt0oEO1IKQhPwPdvCAc8cIDILGpEGP7y3TMfTGTHC__L_NEi\" rel=\"nofollow\" target=\"_blank\">OKYO<\/a>), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company\u2019s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.<\/p>\n<p>\n        <strong>About OKYO<\/strong><br \/>\n        <strong>Pharma <\/strong>\n      <\/p>\n<p>OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.<\/p>\n<p>For further information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HgWtwnWUw6XeI7hxhaA5BhO6s12NEErvVuCOgSALjCwQHWD2QS_s-j4KL1BD7ivL9ENAPgRFEBgeRukQVq5AOSFmbO-1AGiyLD4T1t6hfG8=\" rel=\"nofollow\" target=\"_blank\">www.okyopharma.com<\/a>.<\/p>\n<p>\n        <strong>For further inquiries:<\/strong>\n      <\/p>\n<p>\n        <strong>OKYO Pharma Ltd<\/strong><br \/>\n        <br \/>Paul Spencer<br \/>Business Development and Investor Relations<br \/>+44 (0) 207 495 2379<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fn99BSQtyzal8XBEUYZEu1UH_Lk9CaC510HsMZ-ROH_UtC2P1jHSWss5mOUSxM30ISU33pOH-g5KEcfHYPEH4ybdmgoE5stMRHfhkVT_uH4=\" rel=\"nofollow\" target=\"_blank\">info@okyopharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTk2M2Y1M2EtNGU0MC00NjZjLTgwYjYtNDc3OTQ4M2NhZjg1LTEyMTI5OTYtMjAyNi0wNy0yMi1lbg==\/tiny\/OKYO-Pharma-LTD.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company\u2019s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-983718","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company\u2019s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to &hellip; Continue reading &quot;OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T20:23:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director\",\"datePublished\":\"2026-07-22T20:23:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/\"},\"wordCount\":182,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/\",\"name\":\"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=\",\"datePublished\":\"2026-07-22T20:23:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/","og_locale":"en_US","og_type":"article","og_title":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director - Market Newsdesk","og_description":"LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company\u2019s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to &hellip; Continue reading \"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-22T20:23:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director","datePublished":"2026-07-22T20:23:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/"},"wordCount":182,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/","name":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=","datePublished":"2026-07-22T20:23:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NjI1MyM3NzE3ODE2IzIyMDE0NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/983718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=983718"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/983718\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=983718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=983718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=983718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}